Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

November 2022 | 99 pages | ID: A009C3256F79EN
Global Markets Direct

Abstracts

Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Drugs In Development, 2022, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 7, 4, 5, 2, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Anemia in Chronic Kidney Disease (Renal Anemia) - Overview
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development
Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products
Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Avesthagen Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corporation, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FortuneRock (China) Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by General Biologics Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Genexine Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Great Bay Bio Holdings Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GSK plc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by HEC Pharma Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by HK inno.N Corp, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Imagine Pharma LLC, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by InSilico Medicine, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Liminal BioSciences Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panion & Bf Biotech Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Shanghai Chemo Wanbang Biopharma Co Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by SunBio Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by UBI Pharma Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Uni-Bio Science Group Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zosano Pharma Corp, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Lifesciences Ltd, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, 2022
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, 2022 (Contd..1)
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022